A humble mindset of the contributions he has made to genitourinary cancer care, Christopher J. Logothetis, MD, is also working to shape the next generation’s minds of medicine to improve outcomes further.
CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.
An abstract is unavailable.
Ghassan K. Abou-Alfa, MD, discusses the findings and key takeaways from the SUMMIT trial, which evaluated the use of neratinib for the treatment of patients…
MDA, 5th Surgical Oncology Advanced Practitioner (SOAP) Conference, 4/24/2025 7:00:00 AM – 4/26/2025 5:30:00 PM, The SOAP (Surgical Oncology Advanced Practitioner) Conference aims to foster…
The FDA has approved tislelizumab plus chemotherapy for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
During the 66th American Society of Hematology Annual Meeting and Exposition, investigators revealed early-phase 1 data evaluating various BTK degraders that leverage different strategies to…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with…
A series of events took John L. Marshall, MD, down his path of becoming a gastrointestinal oncology leader, with a drive that has also solidified…
